Phase I/II Trial of the Anti-HIV Activity of Mifepristone in HIV-Infected Subjects ACTG 5200
Yu Song, Barbara Brizz(Social and Scientific Systems (United States)), Winston Cavert(University of Minnesota Medical Center), Pablo Tebas(University of Pennsylvania), Eric S. Daar(UCLA Medical Center), Jeff Schouten, Dominic N. Reeds(Washington University in St. Louis), Juan J.L. Lertora(National Institutes of Health Clinical Center), Michael F. Para(The Ohio State University), Kristine B. Patterson(University of North Carolina at Chapel Hill), C Jo White, Susan L. Rosenkranz(Harvard University), David B. Weiner(The Wistar Institute)
Cited by 0
Related Papers
Antiretroviral-Drug Resistance among Patients Recently Infected with HIV
|New England Journal of Medicine|2002|1.1k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|891
Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4 <sup>+</sup> T Cells
|Science|1999|872
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission
|Science Translational Medicine|2011|352